Songjiang Ma Sells 2,000 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Posted by Chris Copeland on Mar 15th, 2025

Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $11.74, for a total transaction of $23,480.00. Following the completion of the transaction, the president now directly owns 2,835,260 shares in the company, valued at approximately $33,285,952.40. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Songjiang Ma also recently made the following trade(s):

On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.14, for a total transaction of $20,280.00.
On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.25, for a total value of $20,500.00.
On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.90, for a total value of $23,800.00.
On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.62, for a total value of $23,240.00.
On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.43, for a total value of $22,860.00.
On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total transaction of $22,360.00.
On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total transaction of $20,980.00.
On Tuesday, January 21st, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total transaction of $21,700.00.
On Friday, January 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.72, for a total value of $21,440.00.
On Wednesday, January 15th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.85, for a total value of $21,700.00.

Gyre Therapeutics Stock Up 1.3 %

Shares of GYRE stock opened at $12.11 on Friday. The company has a 50-day moving average of $11.27 and a two-hundred day moving average of $12.31. Gyre Therapeutics, Inc. has a 1-year low of $8.26 and a 1-year high of $19.96.

Wall Street Analyst Weigh In

Separately, Noble Financial started coverage on Gyre Therapeutics in a report on Tuesday. They set an “outperform” rating for the company.

Get Our Latest Stock Analysis on Gyre Therapeutics

Hedge Funds Weigh In On Gyre Therapeutics

A number of hedge funds have recently made changes to their positions in GYRE. FMR LLC acquired a new position in Gyre Therapeutics during the third quarter worth $47,000. Wells Fargo & Company MN raised its holdings in shares of Gyre Therapeutics by 29.4% in the 4th quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock valued at $49,000 after buying an additional 913 shares during the period. Bank of America Corp DE lifted its stake in Gyre Therapeutics by 40.4% during the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after acquiring an additional 1,996 shares in the last quarter. Barclays PLC boosted its holdings in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Gyre Therapeutics by 11.1% in the 4th quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock valued at $168,000 after acquiring an additional 1,389 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.